Christopher Koh1, Sasan Sakiani1,2, Pallavi Surana1, Xiongce Zhao2, Jason Eccleston1, David E Kleiner3, David Herion4, T Jake Liang1, Jay H Hoofnagle1, Milica Chernick5, Theo Heller1. 1. Liver Diseases Branch, National Institutes of Health, Bethesda, MD. 2. Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Cleveland, OH. 3. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD. 4. Department of Clinical Research Informatics, Clinical Center, National Institutes of Health, Bethesda, MD. 5. Office of the Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Abstract
Cystic fibrosis (CF) liver disease (CFLD), a leading cause of death in CF, is mostly described in pediatric populations. Adult-onset CFLD lacks sufficient characterization and diagnostic tools. A cohort of CF patients without CFLD during childhood were followed for up to 38 years with serologic testing, imaging, and noninvasive fibrosis markers. Historical CFLD diagnostic criteria were compared with newly proposed CFLD criteria. Thirty-six CF patients were followed for a median of 24.5 years (interquartile range 15.6-32.9). By the last follow-up, 11 (31%) had died. With conventional criteria, 8 (22%) patients had CFLD; and by the new criteria, 17 (47%) had CFLD at a median age of 36.6 years (interquartile range 26.5-43.2). By the new criteria, those with CFLD had higher median alanine aminotransferase (42 versus 27, P = 0.005), aspartate aminotransferase (AST; 26 versus 21, P = 0.01), direct bilirubin (0.13 versus 0.1, P = 0.01), prothrombin time (14.4 versus 12.4, P = 0.002), and AST-to-platelet ratio index (0.31 versus 0.23, P = 0.003) over the last 2 years of follow-up. Subjects with a FibroScan >6.8 kPa had higher alanine aminotransferase (42 versus 28U/L, P = 0.02), AST (35 versus 25U/L, P = 0.02), AST-to-platelet ratio index (0.77 versus 0.25, P = 0.0004), and Fibrosis-4 index (2.14 versus 0.74, P = 0.0003) and lower platelet counts (205 versus 293, P = 0.02). One CFLD patient had nodular regenerative hyperplasia. Longitudinally, mean platelet counts significantly declined in the CFLD group (from 310 to 230 U/L, P = 0.0005). Deceased CFLD patients had lower platelet counts than those alive with CFLD (143 versus 258 U/L, P = 0.004) or those deceased with no CFLD (143 versus 327U/L, P = 0.006). CONCLUSION: Adult-onset CFLD may be more prevalent than previously described, which suggests a later wave of CFLD that impacts morbidity; routine liver tests, radiologic imaging, noninvasive fibrosis markers, and FibroScan can be used algorithmically to identify adult CFLD; and further evaluation in other CF cohorts should be performed for validation. (Hepatology 2017;66:591-601). Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Cystic fibrosis (CF) liver disease (CFLD), a leading cause of death in CF, is mostly described in pediatric populations. Adult-onset CFLD lacks sufficient characterization and diagnostic tools. A cohort of CFpatients without CFLD during childhood were followed for up to 38 years with serologic testing, imaging, and noninvasive fibrosis markers. Historical CFLD diagnostic criteria were compared with newly proposed CFLD criteria. Thirty-six CFpatients were followed for a median of 24.5 years (interquartile range 15.6-32.9). By the last follow-up, 11 (31%) had died. With conventional criteria, 8 (22%) patients had CFLD; and by the new criteria, 17 (47%) had CFLD at a median age of 36.6 years (interquartile range 26.5-43.2). By the new criteria, those with CFLD had higher median alanine aminotransferase (42 versus 27, P = 0.005), aspartate aminotransferase (AST; 26 versus 21, P = 0.01), direct bilirubin (0.13 versus 0.1, P = 0.01), prothrombin time (14.4 versus 12.4, P = 0.002), and AST-to-platelet ratio index (0.31 versus 0.23, P = 0.003) over the last 2 years of follow-up. Subjects with a FibroScan >6.8 kPa had higher alanine aminotransferase (42 versus 28U/L, P = 0.02), AST (35 versus 25U/L, P = 0.02), AST-to-platelet ratio index (0.77 versus 0.25, P = 0.0004), and Fibrosis-4 index (2.14 versus 0.74, P = 0.0003) and lower platelet counts (205 versus 293, P = 0.02). One CFLD patient had nodular regenerative hyperplasia. Longitudinally, mean platelet counts significantly declined in the CFLD group (from 310 to 230 U/L, P = 0.0005). Deceased CFLD patients had lower platelet counts than those alive with CFLD (143 versus 258 U/L, P = 0.004) or those deceased with no CFLD (143 versus 327U/L, P = 0.006). CONCLUSION: Adult-onset CFLD may be more prevalent than previously described, which suggests a later wave of CFLD that impacts morbidity; routine liver tests, radiologic imaging, noninvasive fibrosis markers, and FibroScan can be used algorithmically to identify adult CFLD; and further evaluation in other CF cohorts should be performed for validation. (Hepatology 2017;66:591-601). Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Matthew D Sadler; Pam Crotty; Linda Fatovich; Stephanie Wilson; Harvey R Rabin; Robert P Myers Journal: Can J Gastroenterol Hepatol Date: 2015-04
Authors: Amal Aqul; Maureen M Jonas; Sarah Harney; Roshan Raza; Gregory S Sawicki; Paul D Mitchell; Rima Fawaz Journal: J Pediatr Gastroenterol Nutr Date: 2017-04 Impact factor: 2.839
Authors: C Koh; T Heller; V Haynes-Williams; K Hara; X Zhao; J J Feld; D E Kleiner; Y Rotman; M G Ghany; T J Liang; J H Hoofnagle Journal: Aliment Pharmacol Ther Date: 2013-03-06 Impact factor: 8.171
Authors: S J Schwarzenberg; C L Wielinski; I Shamieh; B L Carpenter; J Jessurun; S A Weisdorf; W J Warwick; H L Sharp Journal: J Pediatr Date: 1995-10 Impact factor: 4.406
Authors: Simon C Ling; Wen Ye; Daniel H Leung; Oscar M Navarro; Alexander Weymann; Wikrom Karnsakul; A Jay Freeman; John C Magee; Michael R Narkewicz Journal: J Pediatr Gastroenterol Nutr Date: 2019-09 Impact factor: 2.839
Authors: Jessica P Woolfson; Richard A Schreiber; Shraavan Raveendran; Mark Chilvers; Collin Barker; Orlee R Guttman Journal: Can Liver J Date: 2021-02-24
Authors: Marilyn J Siegel; A Jay Freeman; Wen Ye; Joseph J Palermo; Jean P Molleston; Shruti M Paranjape; Janis Stoll; Daniel H Leung; Prakash Masand; Boaz Karmazyn; Roger Harned; Simon C Ling; Oscar M Navarro; Wikrom Karnsakul; Adina Alazraki; Sarah Jane Schwarzenberg; Frank Glen Seidel; Alex Towbin; Estella M Alonso; Jennifer L Nicholas; Karen F Murray; Randolph K Otto; Averell H Sherker; John C Magee; Michael R Narkewicz Journal: J Pediatr Date: 2020-02-12 Impact factor: 4.406
Authors: Cristiane J Nunes-Santos; Christopher Koh; Anjali Rai; Keith Sacco; Beatriz E Marciano; David E Kleiner; Jamie Marko; Jenna R E Bergerson; Michael Stack; Maria M Rivera; Gregory Constantine; Warren Strober; Gulbu Uzel; Ivan J Fuss; Luigi D Notarangelo; Steven M Holland; Sergio D Rosenzweig; Theo Heller Journal: J Allergy Clin Immunol Date: 2021-06-01 Impact factor: 10.793